Furthermore, Luciani et al
Chinas Oral GLP-1 market is expanding rapidly in 2025 due to the countrys rising diabetes and obesity rates, with nearly 148 million diabetic adults and over 60% of the population overweight or obese, creating strong demand for effective glucose-lowering and weight-management therapies
For athletes, this means more training volume without hitting the wall , faster turnaround between sessions, and a metabolic environment that supports both performance and physique goals
Tucker S, Bramante C, Conroy M, et al
GLP-1 medications offer real benefits for weight and blood sugar management but those benefits should not come at the cost of bone density, muscle function, or immune health